- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04698629
Hepatitis C Pharmacy-based Strategy for Injectors (HepPSI)
Pilot Study of a Community-Pharmacy Model to Expand Access to Medications to Treat and Prevent Hepatitis C, Opioid Use Disorders, Overdose and HIV Among Persons Who Inject Drugs
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Single-arm, prospective observational study of 40 adult persons who inject drugs (PWID) who screen positive for hepatitis C virus (HCV) with a reactive antibody test at community sites who are offered facilitated linkage to community-pharmacy program through patient navigators. Individuals who are eligible and enroll will complete a baseline survey to assess sociodemographics, substance use, HIV risk behaviors, and awareness of and interest in HCV treatment. After the survey, the participants will be linked to the community-pharmacy program, via the patient navigator, where treatment for HCV and opioid use disorder (OUD), as well as pre-exposure prophylaxis (PrEP), Naloxone and vaccinations, will be offered to participants.
After 6 months, participants will complete a follow-up survey, which will include questions on: whether an evaluation for HCV occurred at the community pharmacy, whether HCV treatment was initiated since baseline visit, substance use, HIV risk behaviors, receipt of medications to treat HCV, opioid use disorder, Naloxone and PrEP receipt, medication adherence, and injecting network.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98104
- University of Washington
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- >18 years old
- Reports injecting drugs with 90 days of screening
- Positive HCV test documented (screening antibody test or viral load test)
- Not currently taking medications to treat HCV, and never previously treated with direct-acting antivirals (DAAs) for HCV
- Willing to undergo evaluation for HCV through a community pharmacy program and work with Patient Navigators
- Provides release of information (ROI) to access community pharmacy program records and/or other HCV treatment providers
Exclusion Criteria:
- People who plan to leave the Seattle area within 6 months
- Who do not wish to be treated for their HCV infection
- Who are known to be pregnant
- Who report impending incarceration that would disrupt clinical care
- Who are not comfortable reading and speaking English
- Who report being HIV-positive
- Who report having end-stage renal disease or require dialysis treatments
- Who report prior enrolled in (i.e. completed at least the initial intake appointment) the Kelley-Ross pharmacy program for hepatitis C treatment ("One Step Hep C Free")
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Community Pharmacy Program Successful Linkage
Lasso di tempo: 6 months
|
The number/percent of participants who successfully link to the community pharmacy program and are seen for initial evaluation.
|
6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Initiation of HCV Treatment
Lasso di tempo: 6 months
|
The number/percent who initiate medications for HCV.
|
6 months
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Substance Use
Lasso di tempo: 6 months
|
Compare at baseline and 6-month follow-up the number of days of drug use within the past 30 days via self-report using the modified Addition Severity Index (ASI).
|
6 months
|
HIV Drug Risk Behaviors
Lasso di tempo: 6 months
|
Compare at baseline and 6-month follow-up the number of injecting episodes using shared needle/syringe within the past 30 days via self-report using the modified Risk Behaviors Survey (RBS).
|
6 months
|
HIV Sex Risk Behaviors
Lasso di tempo: 6 months
|
Compare at baseline and 6-month follow-up the number of episodes of unprotected vaginal or anal sex within the past 30 days via self-report using the modified Risk Behaviors Survey (RBS).
|
6 months
|
Utilization of Other Community Pharmacy Services
Lasso di tempo: 6 months
|
The number/percent who receive of other medications (naloxone, PrEP, and medications to treat OUD) via the community pharmacy program.
|
6 months
|
Participant Satisfaction and Referral to the Community Pharmacy Program
Lasso di tempo: 6 months
|
Self-reported participant Likert scale surveys of satisfaction and willingness to refer an injecting partner to the community pharmacy for treatment; 1=strongly disagree, 2=disagree, 3=neutral, 4=agree, 5=strongly agree with the level of satisfaction/likelihood of referral to services.
|
6 months
|
Completion of HCV Treatment
Lasso di tempo: 9 months
|
The number/percent who complete treatment for HCV, defined as having received all planned medication doses.
|
9 months
|
Sustained Virologic Response (SVR12)
Lasso di tempo: 12 months
|
SVR12 will be defined as undetectable HCV viral load at least 12-weeks post treatment completion.
|
12 months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Judith I Tsui, MD, MPH, University of Washington
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- STUDY00010476
- R34DA047660 (Sovvenzione/contratto NIH degli Stati Uniti)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .